Midodrine for the early liberation from vasopressor support in the ICU (LIBERATE): A Vanguard Randomized Clinical Trial
Bibliographic record
Abstract
ABSTRACT Background Intravenous (IV) vasopressors are the mainstay of hemodynamic physiological support for critically ill patients. However, the role of oral vasopressors in the management of IV vasopressor-dependent shock remains unclear. The LIBERATE body of work aims to examine the role of midodrine as an IV vasopressor sparing agent for critically ill patients with IV vasopressor dependent shock. The objective of the LIBERATE internal randomized controlled trial was to evaluate the implementation of the LIBERATE protocol in a multi-centre randomized control trial setting. Methods We conducted a pilot multi-centre, concealed-allocation, parallel-group, blinded randomized controlled trial (RCT) evaluating the effect of midodrine 10mg q8h versus placebo on the duration of IV vasopressor-dependent shock in the intensive care unit (ICU) on the first 200 of planned sample size for the LIBERATE trial. The study was performed in 9 Alberta and Ontario medical centres between September 16, 2022 and January 22, 2025. We included patients aged 18 years or older admitted to the ICU receiving ongoing IV vasopressor support. Patients were randomly assigned 1:1 to enteral midodrine or an identical placebo and received the study treatment until 24 hours after discontinuation of their IV vasopressor therapy. The primary endpoints were study feasibility and included: recruitment rate (monthly enrollment per study site), screening and enrollment characteristics, protocol adherence, retention rate, data completeness, and safety (adverse event reporting), Secondary endpoints focused on aggregate patient-centered outcomes. Results There were 200 patients who fulfilled eligibility criteria and were enrolled in the trial. The mean age was 61.7 (SD 15.0), and 80 (40.1%) were female. The mean Acute Physiology and Health Evaluation (APACHE II) score at ICU admission was 23.7 (SD 7.6) and the mean Sequential Organ Failure Assessment (SOFA) score at the time of study enrollment was 10.1 (SD 2.9). Sepsis was the most common cause of shock in both groups. Average recruitment was 1.4 participants (range 0.3 to 3.0) per study site per month, protocol adherence was 84.5%, retention rate was 97.0%, and there were no reports of unblinding of treatment allocation by the study sites. Two adverse events were reported and resolved with no sequelae. Conclusion The LIBERATE internal randomized controlled trial is feasible and safe, supporting a larger trial to investigate the utility of midodrine in critically ill patients with IV vasopressor-dependent shock. Trial Registration Registered September 28, 2021. https://clinicaltrials.gov/study/ NCT05058612 Key messages regarding feasibility It was previously unknown if recruitment rates, protocol adherence and safety of midodrine would remain in effect across multiple centres This internal randomized controlled trial across 9 sites established sufficient feasibility outcomes with recruitment rates of 1.4 participants per site per month, protocol adherence of 84.5%, retention rates of 97.0%, data completeness of 96.0% and adverse event rate attributable to study medication of 0%. The results of this trial will be used to inform and proceed with the LIBERATE RCT.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.007 | 0.009 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.004 | 0.003 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.002 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.010 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".